|
Variables
|
Rosiglitazone
|
|---|
|
Cases
|
Controls
|
Crude OR
|
†Adjusted OR
|
‡Adjusted OR
|
|---|
|
N = 357
|
%
|
N = 1,428
|
%
|
|---|
|
Nonuse
|
323
|
90.5
|
1,217
|
85.2
|
1.00
|
1.00
|
1.00
|
|
Any use
|
34
|
9.5
|
211
|
14.8
|
0.61*
|
0.75
|
1.21
|
|
Recent use
|
10
|
2.8
|
25
|
1.8
|
1.51
|
1.50
|
1.88
|
|
Past use
|
24
|
6.7
|
186
|
13.0
|
0.49*
|
0.62*
|
0.93
|
|
Cumulative dosage
| |
|
< 260 DDDs
|
23
|
6.4
|
94
|
6.6
|
0.92
|
1.14
|
1.69
|
|
≥ 260 DDDs
|
11
|
3.1
|
117
|
8.2
|
0.35*
|
0.44*
|
0.79
|
|
Cumulative duration
| |
|
< 1 year
|
26
|
7.3
|
116
|
8.1
|
0.85
|
1.04
|
1.56
|
|
≥ 1 year
|
8
|
2.2
|
95
|
6.7
|
0.32*
|
0.40*
|
0.74
|
-
†: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, and comorbidities.
-
‡: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, comorbidities, and medications.
-
OR odds ratios, N number.
- *P < 0.05.
